<article xmlns="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle http://dtd.nlm.nih.gov/2.0/xsd/archivearticle.xsd" article-type="review-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Curr Opin Pharmacol</journal-id>
      <journal-title>Current Opinion in Pharmacology</journal-title>
      <issn pub-type="ppub">1471-4892</issn>
      <issn pub-type="epub">1471-4973</issn>
      <publisher>
        <publisher-name>Elsevier Science Ltd.</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">2679984</article-id>
      <article-id pub-id-type="pmid">17611159</article-id>
      <article-id pub-id-type="publisher-id">COPHAR481</article-id>
      <article-id pub-id-type="doi">10.1016/j.coph.2007.05.002</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Novel delivery methods to achieve immunomodulation</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Gould</surname>
            <given-names>David J</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chernajovsky</surname>
            <given-names>Yuti</given-names>
          </name>
          <email>y.chernajovsky@qmul.ac.uk</email>
        </contrib>
      </contrib-group>
      <aff>
        <addr-line>Bone and Joint Research Unit, William Harvey Research Institute, Barts and The London, Queen Mary's School of Medicine and Dentistry, University of London, Charterhouse Square, London EC1M 6BQ, United Kingdom</addr-line>
      </aff>
      <pub-date pub-type="ppub">
        <month>8</month>
        <year>2007</year>
      </pub-date>
      <volume>7</volume>
      <issue>4</issue>
      <fpage>445</fpage>
      <lpage>450</lpage>
      <history/>
      <permissions>
        <copyright-statement>© 2007 Elsevier Ltd.</copyright-statement>
        <copyright-year>2007</copyright-year>
        <copyright-holder>Elsevier Ltd</copyright-holder>
        <license>
          <p>This document may be redistributed and reused, subject to <ext-link ext-link-type="uri" xlink:href="http://www.elsevier.com/wps/find/authorsview.authors/supplementalterms1.0">certain conditions</ext-link>.</p>
        </license>
      </permissions>
      <abstract>
        <p>Immunomodulation in infectious diseases, cancer, cardiovascular disease and autoimmunity can now be targeted by sophisticated protein design, altering cellular responses by increasing therapeutic cell numbers <italic>ex vivo</italic> and then reimplanting, or altering cell function by gene transfer of cells <italic>ex vivo</italic>. In the last year, vaccination has been applied to modulate responses to autoantigens, allergens, viral or cancer antigens. The application of these technologies has entered the clinical arena and is having a positive impact on the treatment and prevention of human diseases.</p>
      </abstract>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Introduction</title>
      <p>Immunomodulation can impact many pathological processes including vaccination, autoimmunity, cancer and transplantation. Using naturally occurring compounds from steroids to antibodies and cytokines has been advantageous for disease management. Yet, their use is limited due to systemic effects on healthy tissue that can lead to unwanted side effects. In this review, we want to focus on new molecular and cellular technologies that are advancing the overall aim of targeting therapy to particular disease sites or mechanisms of disease and hence are more specific.</p>
      <p>Intracellular delivery systems will be required for all molecules that have intracellular function. For example, nucleic acid molecules including encoding genes, oligonucleotides and RNA molecules must enter cells and target the nucleus when transcription is the target. Proteins with intracellular function require delivery into cells. Regardless of the molecules for delivery, a common requirement is the evasion of endosomal uptake that may cause degradation and denaturation. Several approaches are being developed that can be applied to the delivery of all these types of molecules at disease sites. For the goal to be fully achieved, cell-targeting strategies require still further development.</p>
      <p>We concentrate this review on the engineering of molecules and cells that are helping the development of novel therapeutics (see <xref rid="tbl1" ref-type="table">Table 1</xref>). We are not going into the details of the methods of gene therapy as this is beyond the scope of this review.</p>
    </sec>
    <sec>
      <title>Protein delivery systems</title>
      <p>Antibodies against tumour antigens have been used for both diagnostic and therapeutic purposes (see <xref rid="fig1" ref-type="fig">Figure 1</xref>a). The cellular immune response against cancers can be potentiated by delivering cytokines to sites of tumour growth. For this purpose, fusion proteins between anti-tumour antigen antibodies and cytokines (immunocytokines) have been developed [<xref rid="bib1" ref-type="bibr">1</xref>]. A humanised anti-ganglioside GD2 antibody fused with IL-2 was investigated in phase I clinical trials in melanoma [<xref rid="bib2" ref-type="bibr">2<sup>•</sup></xref>] and prostate cancer patients [<xref rid="bib3" ref-type="bibr">3</xref>]. In both cases increased cellular immune responses were reported.</p>
      <p>Immunocytokines provide increased half-life to cytokines, but the antibody moiety has a decreased half-life when compared with the non-fused protein. This is probably due to the interactions of immunocytokines with cytokine receptors that are widely expressed throughout the body. In this respect, engineering latent cytokines [<xref rid="bib4 bib5" ref-type="bibr">4<sup>•</sup>,5</xref>] overcome the interaction with cytokine receptors. Latent cytokines are fusion proteins between the latent-associated peptide (LAP) from transforming growth factor (TGF) β followed by a matrix metalloproteinase (MMP) cleavage site and the cytokine of interest. The LAP dimer encloses the cytokine in a shell-like structure conferring extended half-life to the cytokine that cannot interact with its receptor(s) until released from LAP at sites of high MMP activity found in pathologies with local inflammation and active tissue remodeling such as autoimmune disease, atherosclerosis and cancer.</p>
      <p>Protein transduction domains (PTDs) are peptide sequences that can penetrate cell membranes independent of interaction with specific receptors or transporters. The first characterised PTD is the third α helix of Antennapedia homeodomain protein [<xref rid="bib6" ref-type="bibr">6</xref>] whilst a region of HIV Tat containing a basic domain is probably the most widely applied PTD [<xref rid="bib7" ref-type="bibr">7</xref>] (for review on PTDs see Reference [<xref rid="bib8" ref-type="bibr">8</xref>]). The uptake mechanism for Tat is via a lipid raft-dependent macropinocytosis mechanism [<xref rid="bib9" ref-type="bibr">9<sup>•</sup></xref>]. Following cell entry Tat targets molecules to the nucleus because of a strong nuclear localisation signal unless this signal is overridden by a nuclear export signal in the cargo molecule. In view of PTDs’ lack of immunogenicity, and versatility as carriers of a variety of molecules (proteins, peptides, siRNA, DNA–protein complexes and viruses) of unlimited size, their clinical application seems likely in the near future. The versatility of these molecules is illustrated in a recent study where PTDs were used to deliver pre-mRNA to correct aberrant splicing of a gene [<xref rid="bib10" ref-type="bibr">10</xref>]. Also Bim, an antagonist of Bcl-2-mediated cell survival, was delivered to tumour cells with Tat that significantly slowed down tumour growth in murine models of pancreatic cancer and melanoma [<xref rid="bib11" ref-type="bibr">11</xref>]. Another potential strategy for cancer treatment utilising a PTD is delivery of HSV-TK fused with Tat (TK-Tat), and in this <italic>in vitro</italic> study TK-Tat localised to the nucleus was stable and cells were sensitive to ganciclovir treatment with good bystander killing observed [<xref rid="bib12" ref-type="bibr">12</xref>]. PTDs have been employed for immunomodulation in experimental models of inflammation; for example, the delivery of the Tat-IκBα superrepressor in a rat pleurisy model caused a reduction in both leucocyte recruitment and production of proinflammatory cytokines [<xref rid="bib13" ref-type="bibr">13</xref>]. One interesting strategy is the use of a short amphipathic peptide carrier, Pep-1, which can be linked non-covalently to cargo molecules through Fmoc, which then dissociates immediately after it has crossed the cell membrane [<xref rid="bib14" ref-type="bibr">14</xref>] and the liberated cargo can then distribute with normal tropism without influence from the attached PTD.</p>
      <p>Human papilloma virus (HPV) has proven hard to eradicate because of ineffective means of <italic>in vitro</italic> culture. Cloning of the HPV capsid gene (L1) and its expression in heterologous systems [<xref rid="bib15" ref-type="bibr">15</xref>] has allowed the development of effective vaccines. Hence, prophylactic vaccination to HPV types 6/11/16 and18 to prevent cervical cancer is becoming a reality [<xref rid="bib16" ref-type="bibr">16<sup>•</sup></xref>].</p>
    </sec>
    <sec>
      <title>New viral gene delivery systems</title>
      <p>Somatic gene therapy was originally thought to be safer using non-replicating viruses. However, for cancer treatment scientists have now developed attenuated viruses that are capable of replicating more efficiently in cancer cells than in normal cells. These oncolytic viruses could in principle infect neighbouring cancer cells and lyse them sparing the normal tissue. A wide variety of RNA and DNA viruses are being investigated [<xref rid="bib17" ref-type="bibr">17</xref>]. Replicating poxvirus can deliver antiangiogenic factors both as secreted factors or as shRNA [<xref rid="bib18 bib19" ref-type="bibr">18,19</xref>] or cytokines such as GM-CSF [<xref rid="bib20" ref-type="bibr">20</xref>]. Recently, the data of a phase I clinical trial in prostate cancer using intravenous injection of a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus were published with some positive results [<xref rid="bib21" ref-type="bibr">21<sup>•</sup></xref>].</p>
      <p>The use of oncolytic viruses, the relevance of the animal models and the environmental safety issues involved raised some concerns [<xref rid="bib22" ref-type="bibr">22</xref>]. The immune system appears to be dealing quite effectively with these oncolytic viruses because most humans are preimmune to these viruses either via natural exposure or by vaccination. Whether the antiviral immune response will allow for effective cancer therapy will need to be resolved in clinical trials.</p>
    </sec>
    <sec>
      <title>Non-viral delivery systems</title>
      <p>Plasmid DNA has no innate mechanism to enter cells, but direct injection in skeletal muscle achieves transfection and gene expression in most species from rodents [<xref rid="bib23" ref-type="bibr">23<sup>•</sup></xref>] to humans [<xref rid="bib24" ref-type="bibr">24<sup>•</sup></xref>]. This expression has led to the effective application of plasmid vectors in numerous vaccination studies conducted in rodents. DNA-based vaccines have several advantages including their simple preparation and stability. Vaccination is more flexible because the plasmid encoding the antigen can be combined with other genes that modify the immune response. Plasmid DNA also has immunostimulatory properties due to unmethylated CpG repeats that interact with TLR9 receptors expressed on antigen-presenting cells (APC), although this is not a prerequisite for vaccination as responses are also observed in TLR9-knockout mice [<xref rid="bib25" ref-type="bibr">25</xref>]. Interestingly, the effectiveness of DNA vaccines in small animals has not translated to primates and humans and proof of activity in clinical trials has only recently been reported. In a phase I trial a DNA vaccine for bird flu was shown to be safe and achieved antibody responses at tested doses [<xref rid="bib26" ref-type="bibr">26</xref>]. Transfection of plasmid DNA in skeletal muscle is efficiently enhanced in rodents by the use of electroporation that opens pores in the cells to permit direct entry of DNA [<xref rid="bib27" ref-type="bibr">27</xref>]. Electroporation can enhance DNA vaccination [<xref rid="bib28" ref-type="bibr">28</xref>], but there are few reports using electroporation in large animals. However, hydrodynamic delivery of plasmid DNA or siRNA into the vasculature of an occluded limb has proven equally effective in primates and rodents [<xref rid="bib29" ref-type="bibr">29<sup>•</sup></xref>].</p>
      <p>Nucleic acid molecules also need to be delivered intracellularly for function to the nucleus (for gene transcription, or for transcriptional decoy effects) or to the cytoplasm for inhibition of RNA translation or to target mRNA degradation (antisense RNA, ribozymes). RNA interference (RNAi) is an endogenous mechanism whereby double stranded RNA is processed by the RNAse III-like protein Dicer to produce short interfering RNA (siRNA) that are incorporated into the RNA-induced silencing complex (RISC) [<xref rid="bib30" ref-type="bibr">30</xref>]. Synthetic siRNA are structurally related to endogenous microRNAs (miRNA) and can be used for sequence specific silencing. Bevasiranib, an siRNA targeting VEGF mRNA, is already in phase II clinical trials for the treatment of wet age-related macular degeneration [<xref rid="bib31" ref-type="bibr">31</xref>]. These small molecules were applied in a variety of experimental models in saline, complexed with lipids or conjugated with molecules for improved pharmacokinetics or targeting [<xref rid="bib32" ref-type="bibr">32</xref>]. Another interesting aspect of these molecules relevant to immunomodulation is their interaction with Toll-like receptor (TLR)-7 through which they can co-deliver an immunostimulatory response. In a recent study, immunostimulation was further enhanced with an siRNA targeting expression of IL-10 in combination with the TLR-7 stimulation by the molecule [<xref rid="bib33" ref-type="bibr">33</xref>].</p>
      <p>siRNA was used in arthritis models for targeting TNFα. siRNA was delivered to knee joints in combination with electroporation [<xref rid="bib34 bib35" ref-type="bibr">34,35</xref>] or systemically complexed with cationic liposomes [<xref rid="bib36" ref-type="bibr">36</xref>]. Both approaches required re-administration. This transient action is clearly a shortcoming for long-term effects in the treatment of chronic diseases such as rheumatoid arthritis. An alternative is the use of short hairpin RNA (shRNA) molecules expressed long term from gene delivery vectors. shRNA are additionally processed in the nucleus by an RNAse III protein (Drosha) producing pre-miRNA which are exported to the cytoplasm for further processing by Dicer to produce mature miRNA.</p>
      <p>Ribozymes are catalytic RNA molecules that cleave mRNA sequences. Their design is more complex than siRNA. Recently, a hammerhead ribozyme targeting TNFα was shown to inhibit a model of arthritis when delivered intravenously before onset of the disease [<xref rid="bib37" ref-type="bibr">37</xref>].</p>
      <p>Naked DNA and RNA molecules can be combined with a variety of polycations in polyplexes for delivery to cells. The polycations used have different characteristics including ease of DNA unpackaging that is influenced by their molecular weight, toxicity, stability and ability to facilitate endosomal escape. Polyethylenimine (PEI), for example, is a polycation with strong endosome escape properties. To decrease the toxicity of polycations and retain their stability, reducible polycations are used that are specifically cleaved within cells to release the DNA. Synthetic vectors based on reducible (thiol-containing) polycations consisting of histidine and polylysine residues were shown to efficiently deliver DNA, mRNA and siRNA in a variety of different cells [<xref rid="bib38" ref-type="bibr">38</xref>]. The reducible approach has also been used to coat PEI complexes [<xref rid="bib39" ref-type="bibr">39</xref>].</p>
      <p>To target liposomes, phage peptide libraries are used to screen for tissue-binding peptides <italic>in vivo</italic>, for example, in cancer [<xref rid="bib40" ref-type="bibr">40</xref>] or synovial endothelium in arthritis [<xref rid="bib41" ref-type="bibr">41<sup>•</sup></xref>]. These selected peptides can be conjugated to liposomes in order to target their cell of interest.</p>
    </sec>
    <sec>
      <title>Cell delivery systems</title>
      <p>The principle of immunosurveillance has always been central to immunotherapy approaches for the treatment of cancer. Despite the myriad of mechanisms by which cancer cells evade immunosurveillance, it has now been shown that infusion of autologous tumour antigen-specific T cells expanded <italic>ex vivo</italic> are therapeutic [<xref rid="bib42" ref-type="bibr">42</xref>].</p>
      <p>Another method for T cell therapy of cancer is the development of T bodies [<xref rid="bib43" ref-type="bibr">43</xref>] in which chimeric receptors with extracellular scFv (see <xref rid="fig1" ref-type="fig">Figure 1</xref>b) of antibodies against tumour antigens are grafted onto the cytoplasmic and signaling domains of T cell receptor (TCR) subunits (see <xref rid="fig1" ref-type="fig">Figure 1</xref>c). The direct recognition of antigen by the scFv obviates the need for antigen processing and presentation by the major histocompatibility complex. In a clinical trial using T bodies, targeting of the tumour sites was poor and survival of the engineered cells very limited [<xref rid="bib44" ref-type="bibr">44</xref>]. This may be due in part to the fact that the scFv used was of mouse origin. Similar work has also been done by cloning α and β chains of TCR from tumour infiltrating lymphocytes with some degree of success in melanoma [<xref rid="bib45 bib46" ref-type="bibr">45<sup>•</sup>,46</xref>]. It is of interest that the fate of the endogenous TCR chains of the transduced cells is unknown. Whether the endogenous TCR chains recognise autoantigens by themselves or by combination with the transduced TCR chains could have consequences for autoimmunity and needs a long-term follow-up of these patients.</p>
      <p>Mesenchymal stromal cells (MSC) have immunosuppressive properties. Transplantation of MSC has been shown to inhibit steroid-resistant grade III–IV graft versus host disease (GvHD) in patients receiving allogeneic stem cell therapy [<xref rid="bib47 bib48" ref-type="bibr">47<sup>•</sup>,48</xref>]. MSC seem to affect the cytokine secretion profile of dendritic cells (DCs), naive and effector T helper cells, and natural killer (NK) cells to induce a more anti-inflammatory or tolerant phenotype [<xref rid="bib49" ref-type="bibr">49<sup>•</sup></xref>].</p>
      <p>GvHD is mediated by T cells from donor origin. T cells can be retrovirally transduced, after cell cycle activation <italic>ex vivo</italic> with anti-CD28/CD3 or phytohaemaglutinin, to express the ‘suicidal’ gene thymidine kinase from Herpes simplex virus (HSV tk) that renders dividing T cells sensitive to ganciclovir, and this approach has been used in clinical trials [<xref rid="bib50 bib51" ref-type="bibr">50,51</xref>]. Recently, it has been shown that using IL-7-mediated proliferation of T cells preserves the effector function of T cells more effectively than TCR-mediated protocols for viral transduction [<xref rid="bib52" ref-type="bibr">52<sup>•</sup></xref>].</p>
    </sec>
    <sec>
      <title>Conclusions</title>
      <p>The ingenuity of scientists and the exponential growth in the understanding of molecular mechanisms involved in different pathologies have increased substantially the possibilities for immunomodulation. The potential of novel approaches such as gene therapy and drug design enable targeting of therapeutics with better therapeutic index. The limitation of these therapies resides in our better understanding of the long-term outcome of delivering biologicals and manipulating the immune system. The immune system is finely tuned in health to react to foreign pathogens and oncogenic changes of cells in the body. Tilting the immune system with therapeutic agents to behave in a particular way is not without consequences. The challenge for immunomodulating therapies will be to obtain long-lived therapeutic outcomes with shorter therapeutic interventions. This may require the combination of immunotherapies alone or with stem cell therapies.</p>
    </sec>
    <sec>
      <title>References and recommended reading</title>
      <p>Papers of particular interest, published within the annual period of review, have been highlighted as:<list list-type="simple"><list-item><p>• of special interest</p></list-item><list-item><p>•• of outstanding interest</p></list-item></list></p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgements</title>
      <p>We acknowledge support of the Arthritis Research Campaign, UK, EUFP6 (Genostem), the British Heart Foundation and The Wellcome Trust. We are grateful to G Adams for the editing of the manuscript.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="bib1">
        <label>1</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lo</surname>
              <given-names>K.M.</given-names>
            </name>
            <name>
              <surname>Lan</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Lauder</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Brunkhorst</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Qin</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Verma</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Courtenay-Luck</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Gillies</surname>
              <given-names>S.D.</given-names>
            </name>
          </person-group>
          <article-title>huBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumours and tumour vasculature, shows potent anti-tumour activity in human tumour models</article-title>
          <source>Cancer Immunol Immunother</source>
          <year>2007</year>
          <volume>56</volume>
          <fpage>447</fpage>
          <lpage>457</lpage>
          <pub-id pub-id-type="pmid">16874486</pub-id>
        </citation>
      </ref>
      <ref id="bib2">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>King</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Albertini</surname>
              <given-names>M.R.</given-names>
            </name>
            <name>
              <surname>Schalch</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Hank</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Gan</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Surfus</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Mahvi</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Schiller</surname>
              <given-names>J.H.</given-names>
            </name>
            <name>
              <surname>Warner</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients</article-title>
          <source>J Clin Oncol</source>
          <year>2004</year>
          <volume>22</volume>
          <fpage>4463</fpage>
          <lpage>4473</lpage>
          <pub-id pub-id-type="pmid">15483010</pub-id>
        </citation>
        <note>
          <p>First report of clinical trial in cancer using immunocytokines.</p>
        </note>
      </ref>
      <ref id="bib3">
        <label>3</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ko</surname>
              <given-names>Y.J.</given-names>
            </name>
            <name>
              <surname>Bubley</surname>
              <given-names>G.J.</given-names>
            </name>
            <name>
              <surname>Weber</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Redfern</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Gold</surname>
              <given-names>D.P.</given-names>
            </name>
            <name>
              <surname>Finke</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Kovar</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Dahl</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Gillies</surname>
              <given-names>S.D.</given-names>
            </name>
          </person-group>
          <article-title>Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer</article-title>
          <source>J Immunother</source>
          <year>2004</year>
          <volume>27</volume>
          <fpage>232</fpage>
          <lpage>239</lpage>
          <pub-id pub-id-type="pmid">15076141</pub-id>
        </citation>
      </ref>
      <ref id="bib4">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Adams</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Vessillier</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Dreja</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Chernajovsky</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>Targeting cytokines to inflammation sites</article-title>
          <source>Nat Biotechnol</source>
          <year>2003</year>
          <volume>21</volume>
          <fpage>1314</fpage>
          <lpage>1320</lpage>
          <pub-id pub-id-type="pmid">14528315</pub-id>
        </citation>
        <note>
          <p>First description of latent cytokine engineering using IFN β as the therapeutic molecule.</p>
        </note>
      </ref>
      <ref id="bib5">
        <label>5</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vessillier</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Adams</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Chernajovsky</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>Latent cytokines: development of novel cleavage sites and kinetic analysis of their differential sensitivity to MMP-1 and MMP-3</article-title>
          <source>Protein Eng Des Sel</source>
          <year>2004</year>
          <volume>17</volume>
          <fpage>829</fpage>
          <lpage>835</lpage>
          <pub-id pub-id-type="pmid">15708865</pub-id>
        </citation>
      </ref>
      <ref id="bib6">
        <label>6</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Derossi</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Joliot</surname>
              <given-names>A.H.</given-names>
            </name>
            <name>
              <surname>Chassaing</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Prochiantz</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>The third helix of the Antennapedia homeodomain translocates through biological membranes</article-title>
          <source>J Biol Chem</source>
          <year>1994</year>
          <volume>269</volume>
          <fpage>10444</fpage>
          <lpage>10450</lpage>
          <pub-id pub-id-type="pmid">8144628</pub-id>
        </citation>
      </ref>
      <ref id="bib7">
        <label>7</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vives</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Brodin</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Lebleu</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus</article-title>
          <source>J Biol Chem</source>
          <year>1997</year>
          <volume>272</volume>
          <fpage>16010</fpage>
          <lpage>16017</lpage>
          <pub-id pub-id-type="pmid">9188504</pub-id>
        </citation>
      </ref>
      <ref id="bib8">
        <label>8</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chauhan</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Tikoo</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Kapur</surname>
              <given-names>A.K.</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>The taming of the cell penetrating domain of the HIV Tat: myths and realities</article-title>
          <source>J Control Release</source>
          <year>2007</year>
          <volume>117</volume>
          <fpage>148</fpage>
          <lpage>162</lpage>
          <pub-id pub-id-type="pmid">17196289</pub-id>
        </citation>
      </ref>
      <ref id="bib9">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wadia</surname>
              <given-names>J.S.</given-names>
            </name>
            <name>
              <surname>Stan</surname>
              <given-names>R.V.</given-names>
            </name>
            <name>
              <surname>Dowdy</surname>
              <given-names>S.F.</given-names>
            </name>
          </person-group>
          <article-title>Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis</article-title>
          <source>Nat Med</source>
          <year>2004</year>
          <volume>10</volume>
          <fpage>310</fpage>
          <lpage>315</lpage>
          <pub-id pub-id-type="pmid">14770178</pub-id>
        </citation>
        <note>
          <p>Elucidation of Tat-PTD mechanism of entry via a lipid raft-dependent macropinocytosis.</p>
        </note>
      </ref>
      <ref id="bib10">
        <label>10</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>El-Andaloussi</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Johansson</surname>
              <given-names>H.J.</given-names>
            </name>
            <name>
              <surname>Lundberg</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Langel</surname>
              <given-names>U.</given-names>
            </name>
          </person-group>
          <article-title>Induction of splice correction by cell-penetrating peptide nucleic acids</article-title>
          <source>J Gene Med</source>
          <year>2006</year>
          <volume>8</volume>
          <fpage>1262</fpage>
          <lpage>1273</lpage>
          <pub-id pub-id-type="pmid">16900561</pub-id>
        </citation>
      </ref>
      <ref id="bib11">
        <label>11</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kashiwagi</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>McDunn</surname>
              <given-names>J.E.</given-names>
            </name>
            <name>
              <surname>Goedegebuure</surname>
              <given-names>P.S.</given-names>
            </name>
            <name>
              <surname>Gaffney</surname>
              <given-names>M.C.</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Trinkaus</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Piwnica-Worms</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Hotchkiss</surname>
              <given-names>R.S.</given-names>
            </name>
            <name>
              <surname>Hawkins</surname>
              <given-names>W.G.</given-names>
            </name>
          </person-group>
          <article-title>TAT-Bim induces extensive apoptosis in cancer cells</article-title>
          <source>Ann Surg Oncol</source>
          <year>2007</year>
        </citation>
      </ref>
      <ref id="bib12">
        <label>12</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cao</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Si</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Yuan</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Intracellular localization and sustained prodrug cell killing activity of TAT-HSVTK fusion protein in hepatocelullar carcinoma cells</article-title>
          <source>Mol Cells</source>
          <year>2006</year>
          <volume>21</volume>
          <fpage>104</fpage>
          <lpage>111</lpage>
          <pub-id pub-id-type="pmid">16511352</pub-id>
        </citation>
      </ref>
      <ref id="bib13">
        <label>13</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blackwell</surname>
              <given-names>N.M.</given-names>
            </name>
            <name>
              <surname>Sembi</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Newson</surname>
              <given-names>J.S.</given-names>
            </name>
            <name>
              <surname>Lawrence</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Gilroy</surname>
              <given-names>D.W.</given-names>
            </name>
            <name>
              <surname>Kabouridis</surname>
              <given-names>P.S.</given-names>
            </name>
          </person-group>
          <article-title>Reduced infiltration and increased apoptosis of leukocytes at sites of inflammation by systemic administration of a membrane-permeable IkappaBalpha repressor</article-title>
          <source>Arthritis Rheum</source>
          <year>2004</year>
          <volume>50</volume>
          <fpage>2675</fpage>
          <lpage>2684</lpage>
          <pub-id pub-id-type="pmid">15334484</pub-id>
        </citation>
      </ref>
      <ref id="bib14">
        <label>14</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morris</surname>
              <given-names>M.C.</given-names>
            </name>
            <name>
              <surname>Depollier</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Mery</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Heitz</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Divita</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>A peptide carrier for the delivery of biologically active proteins into mammalian cells</article-title>
          <source>Nat Biotechnol</source>
          <year>2001</year>
          <volume>19</volume>
          <fpage>1173</fpage>
          <lpage>1176</lpage>
          <pub-id pub-id-type="pmid">11731788</pub-id>
        </citation>
      </ref>
      <ref id="bib15">
        <label>15</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Heim</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Widschwendter</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Szedenik</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Geier</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Christensen</surname>
              <given-names>N.D.</given-names>
            </name>
            <name>
              <surname>Bergant</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Concin</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Hopfl</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Specific serologic response to genital human papilloma virus types in patients with vulvar precancerous and cancerous lesions</article-title>
          <source>Am J Obstet Gynecol</source>
          <year>2005</year>
          <volume>192</volume>
          <fpage>1073</fpage>
          <lpage>1083</lpage>
          <pub-id pub-id-type="pmid">15846183</pub-id>
        </citation>
      </ref>
      <ref id="bib16">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Villa</surname>
              <given-names>L.L.</given-names>
            </name>
            <name>
              <surname>Costa</surname>
              <given-names>R.L.</given-names>
            </name>
            <name>
              <surname>Petta</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Andrade</surname>
              <given-names>R.P.</given-names>
            </name>
            <name>
              <surname>Paavonen</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Iversen</surname>
              <given-names>O.E.</given-names>
            </name>
            <name>
              <surname>Olsson</surname>
              <given-names>S.E.</given-names>
            </name>
            <name>
              <surname>Hoye</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Steinwall</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Riis-Johannessen</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up</article-title>
          <source>Br J Cancer</source>
          <year>2006</year>
          <volume>95</volume>
          <fpage>1459</fpage>
          <lpage>1466</lpage>
          <pub-id pub-id-type="pmid">17117182</pub-id>
        </citation>
        <note>
          <p>First long term study on the efficacy of HPV vaccination.</p>
        </note>
      </ref>
      <ref id="bib17">
        <label>17</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>T.C.</given-names>
            </name>
            <name>
              <surname>Kirn</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions</article-title>
          <source>Cancer Res</source>
          <year>2007</year>
          <volume>67</volume>
          <fpage>429</fpage>
          <lpage>432</lpage>
          <pub-id pub-id-type="pmid">17234747</pub-id>
        </citation>
      </ref>
      <ref id="bib18">
        <label>18</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thorne</surname>
              <given-names>S.H.</given-names>
            </name>
            <name>
              <surname>Tam</surname>
              <given-names>B.Y.</given-names>
            </name>
            <name>
              <surname>Kirn</surname>
              <given-names>D.H.</given-names>
            </name>
            <name>
              <surname>Contag</surname>
              <given-names>C.H.</given-names>
            </name>
            <name>
              <surname>Kuo</surname>
              <given-names>C.J.</given-names>
            </name>
          </person-group>
          <article-title>Selective intratumoural amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumour efficacy</article-title>
          <source>Mol Ther</source>
          <year>2006</year>
          <volume>13</volume>
          <fpage>938</fpage>
          <lpage>946</lpage>
          <pub-id pub-id-type="pmid">16469543</pub-id>
        </citation>
      </ref>
      <ref id="bib19">
        <label>19</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yoo</surname>
              <given-names>J.Y.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>J.H.</given-names>
            </name>
            <name>
              <surname>Kwon</surname>
              <given-names>Y.G.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>E.C.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>N.K.</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>H.J.</given-names>
            </name>
            <name>
              <surname>Yun</surname>
              <given-names>C.O.</given-names>
            </name>
          </person-group>
          <article-title>VEGF-specific Short Hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumour growth</article-title>
          <source>Mol Ther</source>
          <year>2007</year>
          <volume>15</volume>
          <fpage>295</fpage>
          <lpage>302</lpage>
          <pub-id pub-id-type="pmid">17235307</pub-id>
        </citation>
      </ref>
      <ref id="bib20">
        <label>20</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>J.H.</given-names>
            </name>
            <name>
              <surname>Oh</surname>
              <given-names>J.Y.</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>B.H.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>D.E.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>J.S.</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>H.E.</given-names>
            </name>
            <name>
              <surname>Roh</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Je</surname>
              <given-names>J.E.</given-names>
            </name>
            <name>
              <surname>Yoon</surname>
              <given-names>J.H.</given-names>
            </name>
            <name>
              <surname>Thorne</surname>
              <given-names>S.H.</given-names>
            </name>
          </person-group>
          <article-title>Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF</article-title>
          <source>Mol Ther</source>
          <year>2006</year>
          <volume>14</volume>
          <fpage>361</fpage>
          <lpage>370</lpage>
          <pub-id pub-id-type="pmid">16905462</pub-id>
        </citation>
      </ref>
      <ref id="bib21">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Small</surname>
              <given-names>E.J.</given-names>
            </name>
            <name>
              <surname>Carducci</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Burke</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Rodriguez</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Fong</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>van Ummersen</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>D.C.</given-names>
            </name>
            <name>
              <surname>Aimi</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Ando</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Working</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer</article-title>
          <source>Mol Ther</source>
          <year>2006</year>
          <volume>14</volume>
          <fpage>107</fpage>
          <lpage>117</lpage>
          <pub-id pub-id-type="pmid">16690359</pub-id>
        </citation>
        <note>
          <p>First report on the clinical use of prostate specific oncolytic virus. 23 patients were treated, 5 patients had a decrease in serum prostate-specific antigen (PSA) of 25% to 49% following a single treatment, including 3 of 8 patients at the highest dose levels.</p>
        </note>
      </ref>
      <ref id="bib22">
        <label>22</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chernajovsky</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Layward</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Lemoine</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>Fighting cancer with oncolytic viruses</article-title>
          <source>BMJ</source>
          <year>2006</year>
          <volume>332</volume>
          <fpage>170</fpage>
          <lpage>172</lpage>
          <pub-id pub-id-type="pmid">16424499</pub-id>
        </citation>
      </ref>
      <ref id="bib23">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wolff</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Malone</surname>
              <given-names>R.W.</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Chong</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Acsadi</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Jani</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Felgner</surname>
              <given-names>P.L.</given-names>
            </name>
          </person-group>
          <article-title>Direct gene transfer into mouse muscle in vivo</article-title>
          <source>Science</source>
          <year>1990</year>
          <volume>247</volume>
          <fpage>1465</fpage>
          <lpage>1468</lpage>
          <pub-id pub-id-type="pmid">1690918</pub-id>
        </citation>
        <note>
          <p>Original report of long term expression from muscle by <italic>in vivo</italic> DNA injection.</p>
        </note>
      </ref>
      <ref id="bib24">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Isner</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Baumgartner</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Rauh</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Schainfeld</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Blair</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Manor</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Razvi</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Symes</surname>
              <given-names>J.F.</given-names>
            </name>
          </person-group>
          <article-title>Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results</article-title>
          <source>J Vasc Surg</source>
          <year>1998</year>
          <volume>28</volume>
          <fpage>964</fpage>
          <lpage>973</lpage>
          <pub-id pub-id-type="pmid">9845647</pub-id>
        </citation>
        <note>
          <p>Important pioneering use of plasmid DNA delivery to express VEGF for the treatment of human disease. This work was expanded also to diabetic limb ischemia and coronary heart disease.</p>
        </note>
      </ref>
      <ref id="bib25">
        <label>25</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Spies</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Hochrein</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Vabulas</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Huster</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Busch</surname>
              <given-names>D.H.</given-names>
            </name>
            <name>
              <surname>Schmitz</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Heit</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Wagner</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice</article-title>
          <source>J Immunol</source>
          <year>2003</year>
          <volume>171</volume>
          <fpage>5908</fpage>
          <lpage>5912</lpage>
          <pub-id pub-id-type="pmid">14634101</pub-id>
        </citation>
      </ref>
      <ref id="bib26">
        <label>26</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Drape</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>Macklin</surname>
              <given-names>M.D.</given-names>
            </name>
            <name>
              <surname>Barr</surname>
              <given-names>L.J.</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Haynes</surname>
              <given-names>J.R.</given-names>
            </name>
            <name>
              <surname>Dean</surname>
              <given-names>H.J.</given-names>
            </name>
          </person-group>
          <article-title>Epidermal DNA vaccine for influenza is immunogenic in humans</article-title>
          <source>Vaccine</source>
          <year>2006</year>
          <volume>24</volume>
          <fpage>4475</fpage>
          <lpage>4481</lpage>
          <pub-id pub-id-type="pmid">16150518</pub-id>
        </citation>
      </ref>
      <ref id="bib27">
        <label>27</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mir</surname>
              <given-names>L.M.</given-names>
            </name>
            <name>
              <surname>Bureau</surname>
              <given-names>M.F.</given-names>
            </name>
            <name>
              <surname>Gehl</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Rangara</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Rouy</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Caillaud</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Delaere</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Branellec</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Schwartz</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Scherman</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>High-efficiency gene transfer into skeletal muscle mediated by electric pulses</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>1999</year>
          <volume>96</volume>
          <fpage>4262</fpage>
          <lpage>4267</lpage>
          <pub-id pub-id-type="pmid">10200250</pub-id>
        </citation>
      </ref>
      <ref id="bib28">
        <label>28</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Prud’homme</surname>
              <given-names>G.J.</given-names>
            </name>
            <name>
              <surname>Glinka</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Khan</surname>
              <given-names>A.S.</given-names>
            </name>
            <name>
              <surname>Draghia-Akli</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Electroporation-enhanced nonviral gene transfer for the prevention or treatment of immunological, endocrine and neoplastic diseases</article-title>
          <source>Curr Gene Ther</source>
          <year>2006</year>
          <volume>6</volume>
          <fpage>243</fpage>
          <lpage>273</lpage>
          <pub-id pub-id-type="pmid">16611045</pub-id>
        </citation>
      </ref>
      <ref id="bib29">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hagstrom</surname>
              <given-names>J.E.</given-names>
            </name>
            <name>
              <surname>Hegge</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Noble</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Budker</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Lewis</surname>
              <given-names>D.L.</given-names>
            </name>
            <name>
              <surname>Herweijer</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Wolff</surname>
              <given-names>J.A.</given-names>
            </name>
          </person-group>
          <article-title>A facile nonviral method for delivering genes and siRNAs to skeletal muscle of mammalian limbs</article-title>
          <source>Mol Ther</source>
          <year>2004</year>
          <volume>10</volume>
          <fpage>386</fpage>
          <lpage>398</lpage>
          <pub-id pub-id-type="pmid">15294185</pub-id>
        </citation>
        <note>
          <p>First demonstration of effectiveness of hydrodynamic DNA delivery both in rodents and monkeys.</p>
        </note>
      </ref>
      <ref id="bib30">
        <label>30</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fire</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Montgomery</surname>
              <given-names>M.K.</given-names>
            </name>
            <name>
              <surname>Kostas</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Driver</surname>
              <given-names>S.E.</given-names>
            </name>
            <name>
              <surname>Mello</surname>
              <given-names>C.C.</given-names>
            </name>
          </person-group>
          <article-title>Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans</article-title>
          <source>Nature</source>
          <year>1998</year>
          <volume>391</volume>
          <fpage>806</fpage>
          <lpage>811</lpage>
          <pub-id pub-id-type="pmid">9486653</pub-id>
        </citation>
      </ref>
      <ref id="bib31">
        <label>31</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Michels</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Schmidt-Erfurth</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Rosenfeld</surname>
              <given-names>P.J.</given-names>
            </name>
          </person-group>
          <article-title>Promising new treatments for neovascular age-related macular degeneration</article-title>
          <source>Expert Opin Investig Drugs</source>
          <year>2006</year>
          <volume>15</volume>
          <fpage>779</fpage>
          <lpage>793</lpage>
        </citation>
      </ref>
      <ref id="bib32">
        <label>32</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bumcrot</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Manoharan</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Koteliansky</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Sah</surname>
              <given-names>D.W.</given-names>
            </name>
          </person-group>
          <article-title>RNAi therapeutics: a potential new class of pharmaceutical drugs</article-title>
          <source>Nat Chem Biol</source>
          <year>2006</year>
          <volume>2</volume>
          <fpage>711</fpage>
          <lpage>719</lpage>
          <pub-id pub-id-type="pmid">17108989</pub-id>
        </citation>
      </ref>
      <ref id="bib33">
        <label>33</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Furset</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Sioud</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Design of bifunctional siRNAs: combining immunostimulation and gene-silencing in one single siRNA molecule</article-title>
          <source>Biochem Biophys Res Commun</source>
          <year>2007</year>
          <volume>352</volume>
          <fpage>642</fpage>
          <lpage>649</lpage>
          <pub-id pub-id-type="pmid">17150189</pub-id>
        </citation>
      </ref>
      <ref id="bib34">
        <label>34</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Inoue</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>K.A.</given-names>
            </name>
            <name>
              <surname>Mazda</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Terauchi</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Arai</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Kishida</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Shin-Ya</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Asada</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Morihara</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Tonomura</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Electro-transfer of small interfering RNA ameliorated arthritis in rats</article-title>
          <source>Biochem Biophys Res Commun</source>
          <year>2005</year>
          <volume>336</volume>
          <fpage>903</fpage>
          <lpage>908</lpage>
          <pub-id pub-id-type="pmid">16179161</pub-id>
        </citation>
      </ref>
      <ref id="bib35">
        <label>35</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schiffelers</surname>
              <given-names>R.M.</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Storm</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Woodle</surname>
              <given-names>M.C.</given-names>
            </name>
            <name>
              <surname>Scaria</surname>
              <given-names>P.V.</given-names>
            </name>
          </person-group>
          <article-title>Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis</article-title>
          <source>Arthritis Rheum</source>
          <year>2005</year>
          <volume>52</volume>
          <fpage>1314</fpage>
          <lpage>1318</lpage>
          <pub-id pub-id-type="pmid">15818667</pub-id>
        </citation>
      </ref>
      <ref id="bib36">
        <label>36</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Khoury</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Louis-Plence</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Escriou</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Noel</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Largeau</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Cantos</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Scherman</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Jorgensen</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Apparailly</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumour necrosis factor alpha in experimental arthritis</article-title>
          <source>Arthritis Rheum</source>
          <year>2006</year>
          <volume>54</volume>
          <fpage>1867</fpage>
          <lpage>1877</lpage>
          <pub-id pub-id-type="pmid">16729293</pub-id>
        </citation>
      </ref>
      <ref id="bib37">
        <label>37</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kumar</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Dammai</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Yadava</surname>
              <given-names>P.K.</given-names>
            </name>
            <name>
              <surname>Kleinau</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Gene targeting by ribozyme against TNF-alpha mRNA inhibits autoimmune arthritis</article-title>
          <source>Gene Ther</source>
          <year>2005</year>
          <volume>12</volume>
          <fpage>1486</fpage>
          <lpage>1493</lpage>
          <pub-id pub-id-type="pmid">16034454</pub-id>
        </citation>
      </ref>
      <ref id="bib38">
        <label>38</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Read</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Ahmed</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Stevenson</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Briggs</surname>
              <given-names>S.S.</given-names>
            </name>
            <name>
              <surname>Oupicky</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Barrett</surname>
              <given-names>L.B.</given-names>
            </name>
            <name>
              <surname>Spice</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Kendall</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Berry</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>A versatile reducible polycation-based system for efficient delivery of a broad range of nucleic acids</article-title>
          <source>Nucleic Acids Res</source>
          <year>2005</year>
          <volume>33</volume>
          <fpage>e86</fpage>
          <pub-id pub-id-type="pmid">15914665</pub-id>
        </citation>
      </ref>
      <ref id="bib39">
        <label>39</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carlisle</surname>
              <given-names>R.C.</given-names>
            </name>
            <name>
              <surname>Etrych</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Briggs</surname>
              <given-names>S.S.</given-names>
            </name>
            <name>
              <surname>Preece</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Ulbrich</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Seymour</surname>
              <given-names>L.W.</given-names>
            </name>
          </person-group>
          <article-title>Polymer-coated polyethylenimine/DNA complexes designed for triggered activation by intracellular reduction</article-title>
          <source>J Gene Med</source>
          <year>2004</year>
          <volume>6</volume>
          <fpage>337</fpage>
          <lpage>344</lpage>
          <pub-id pub-id-type="pmid">15026995</pub-id>
        </citation>
      </ref>
      <ref id="bib40">
        <label>40</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Akita</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Maruta</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Seymour</surname>
              <given-names>L.W.</given-names>
            </name>
            <name>
              <surname>Kerr</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Parker</surname>
              <given-names>A.L.</given-names>
            </name>
            <name>
              <surname>Asai</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Oku</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Nakayama</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Miyagawa</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Identification of oligopeptides binding to peritoneal tumours of gastric cancer</article-title>
          <source>Cancer Sci</source>
          <year>2006</year>
          <volume>97</volume>
          <fpage>1075</fpage>
          <lpage>1081</lpage>
          <pub-id pub-id-type="pmid">16984380</pub-id>
        </citation>
      </ref>
      <ref id="bib41">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Buckley</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Blades</surname>
              <given-names>M.C.</given-names>
            </name>
            <name>
              <surname>Panayi</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>George</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Pitzalis</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Identification of synovium-specific homing peptides by in vivo phage display selection</article-title>
          <source>Arthritis Rheum</source>
          <year>2002</year>
          <volume>46</volume>
          <fpage>2109</fpage>
          <lpage>2120</lpage>
          <pub-id pub-id-type="pmid">12209516</pub-id>
        </citation>
        <note>
          <p>First description of peptide-specific targeting to synovial endothelium.</p>
        </note>
      </ref>
      <ref id="bib42">
        <label>42</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mackensen</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Meidenbauer</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Vogl</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Laumer</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Berger</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Andreesen</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma</article-title>
          <source>J Clin Oncol</source>
          <year>2006</year>
          <volume>24</volume>
          <fpage>5060</fpage>
          <lpage>5069</lpage>
          <pub-id pub-id-type="pmid">17075125</pub-id>
        </citation>
      </ref>
      <ref id="bib43">
        <label>43</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eshhar</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Bach</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Fitzer-Attas</surname>
              <given-names>C.J.</given-names>
            </name>
            <name>
              <surname>Gross</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Lustgarten</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Waks</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Schindler</surname>
              <given-names>D.G.</given-names>
            </name>
          </person-group>
          <article-title>The T-body approach: potential for cancer immunotherapy</article-title>
          <source>Springer Semin Immunopathol</source>
          <year>1996</year>
          <volume>18</volume>
          <fpage>199</fpage>
          <lpage>209</lpage>
          <pub-id pub-id-type="pmid">8908700</pub-id>
        </citation>
      </ref>
      <ref id="bib44">
        <label>44</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kershaw</surname>
              <given-names>M.H.</given-names>
            </name>
            <name>
              <surname>Westwood</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Parker</surname>
              <given-names>L.L.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Eshhar</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Mavroukakis</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>White</surname>
              <given-names>D.E.</given-names>
            </name>
            <name>
              <surname>Wunderlich</surname>
              <given-names>J.R.</given-names>
            </name>
            <name>
              <surname>Canevari</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Rogers-Freezer</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer</article-title>
          <source>Clin Cancer Res</source>
          <year>2006</year>
          <volume>12</volume>
          <fpage>6106</fpage>
          <lpage>6115</lpage>
          <pub-id pub-id-type="pmid">17062687</pub-id>
        </citation>
      </ref>
      <ref id="bib45">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morgan</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Dudley</surname>
              <given-names>M.E.</given-names>
            </name>
            <name>
              <surname>Wunderlich</surname>
              <given-names>J.R.</given-names>
            </name>
            <name>
              <surname>Hughes</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Sherry</surname>
              <given-names>R.M.</given-names>
            </name>
            <name>
              <surname>Royal</surname>
              <given-names>R.E.</given-names>
            </name>
            <name>
              <surname>Topalian</surname>
              <given-names>S.L.</given-names>
            </name>
            <name>
              <surname>Kammula</surname>
              <given-names>U.S.</given-names>
            </name>
            <name>
              <surname>Restifo</surname>
              <given-names>N.P.</given-names>
            </name>
          </person-group>
          <article-title>Cancer regression in patients after transfer of genetically engineered lymphocytes</article-title>
          <source>Science</source>
          <year>2006</year>
          <volume>314</volume>
          <fpage>126</fpage>
          <lpage>129</lpage>
          <pub-id pub-id-type="pmid">16946036</pub-id>
        </citation>
        <note>
          <p>Reports the successful use of engineered T cells with TCR genes targeting cancer antigens.</p>
        </note>
      </ref>
      <ref id="bib46">
        <label>46</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Johnson</surname>
              <given-names>L.A.</given-names>
            </name>
            <name>
              <surname>Heemskerk</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Powell</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>C.J.</given-names>
            </name>
            <name>
              <surname>Morgan</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Dudley</surname>
              <given-names>M.E.</given-names>
            </name>
            <name>
              <surname>Robbins</surname>
              <given-names>P.F.</given-names>
            </name>
            <name>
              <surname>Rosenberg</surname>
              <given-names>S.A.</given-names>
            </name>
          </person-group>
          <article-title>Gene transfer of tumour-reactive TCR confers both high avidity and tumour reactivity to nonreactive peripheral blood mononuclear cells and tumour-infiltrating lymphocytes</article-title>
          <source>J Immunol</source>
          <year>2006</year>
          <volume>177</volume>
          <fpage>6548</fpage>
          <lpage>6559</lpage>
          <pub-id pub-id-type="pmid">17056587</pub-id>
        </citation>
      </ref>
      <ref id="bib47">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Le Blanc</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Rasmusson</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Sundberg</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Gotherstrom</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Hassan</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Uzunel</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Ringden</surname>
              <given-names>O.</given-names>
            </name>
          </person-group>
          <article-title>Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells</article-title>
          <source>Lancet</source>
          <year>2004</year>
          <volume>363</volume>
          <fpage>1439</fpage>
          <lpage>1441</lpage>
          <pub-id pub-id-type="pmid">15121408</pub-id>
        </citation>
        <note>
          <p>First use of MSC in human clinical trials.</p>
        </note>
      </ref>
      <ref id="bib48">
        <label>48</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ringden</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Uzunel</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Rasmusson</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Remberger</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Sundberg</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Lonnies</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Marschall</surname>
              <given-names>H.U.</given-names>
            </name>
            <name>
              <surname>Dlugosz</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Szakos</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Hassan</surname>
              <given-names>Z.</given-names>
            </name>
          </person-group>
          <article-title>Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease</article-title>
          <source>Transplantation</source>
          <year>2006</year>
          <volume>81</volume>
          <fpage>1390</fpage>
          <lpage>1397</lpage>
          <pub-id pub-id-type="pmid">16732175</pub-id>
        </citation>
      </ref>
      <ref id="bib49">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aggarwal</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Pittenger</surname>
              <given-names>M.F.</given-names>
            </name>
          </person-group>
          <article-title>Human mesenchymal stem cells modulate allogeneic immune cell responses</article-title>
          <source>Blood</source>
          <year>2005</year>
          <volume>105</volume>
          <fpage>1815</fpage>
          <lpage>1822</lpage>
          <pub-id pub-id-type="pmid">15494428</pub-id>
        </citation>
        <note>
          <p>Analysis of the possible mechanisms mediating the immunosuppressive effects of MSC in humans.</p>
        </note>
      </ref>
      <ref id="bib50">
        <label>50</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ciceri</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Bonini</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Gallo-Stampino</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Bordignon</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Modulation of GvHD by suicide-gene transduced donor T lymphocytes: clinical applications in mismatched transplantation</article-title>
          <source>Cytotherapy</source>
          <year>2005</year>
          <volume>7</volume>
          <fpage>144</fpage>
          <lpage>149</lpage>
          <pub-id pub-id-type="pmid">16040393</pub-id>
        </citation>
      </ref>
      <ref id="bib51">
        <label>51</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Recchia</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Bonini</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Magnani</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Urbinati</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Sartori</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Muraro</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Tagliafico</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Bondanza</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Stanghellini</surname>
              <given-names>M.T.</given-names>
            </name>
            <name>
              <surname>Bernardi</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>2006</year>
          <volume>103</volume>
          <fpage>1457</fpage>
          <lpage>1462</lpage>
          <pub-id pub-id-type="pmid">16432223</pub-id>
        </citation>
      </ref>
      <ref id="bib52">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Qasim</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Mackey</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Sinclair</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Chatziandreou</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Kinnon</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Thrasher</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Gaspar</surname>
              <given-names>H.B.</given-names>
            </name>
          </person-group>
          <article-title>Lentiviral vectors for T-cell suicide gene therapy: preservation of T-cell effector function after cytokine-mediated transduction</article-title>
          <source>Mol Ther</source>
          <year>2007</year>
          <volume>15</volume>
          <fpage>355</fpage>
          <lpage>360</lpage>
          <pub-id pub-id-type="pmid">17235314</pub-id>
        </citation>
        <note>
          <p>The use of lentiviral vectors in humans has been argued for several years. This study is an important step forward in their possible use for the treatment of GvHD.</p>
        </note>
      </ref>
    </ref-list>
  </back>
  <floats-wrap>
    <fig id="fig1">
      <label>Figure 1</label>
      <caption>
        <p>Schematic representation of the structure of antibodies, scFv and chimeric scFv signaling receptors. Panel <bold>a</bold> shows the structure of an antibody with its variable heavy (VH), variable light (VL) domains that comprise the antigen recognition/binding site with their respective constant regions (CH and CL). The whole structure is kept together by disulfide bonds. Panel <bold>b</bold> shows the structure of a scFv where the VH and VL are fused via a 15 aminoacid linker of the sequence (GGGGS)<sub>3</sub>. Panel <bold>c</bold> shows the structure of scFv chimeric receptor where the scFv is extracellular and is normally linked to the cytoplasmic signaling domain of a TCR chain such as the FcRγ or the ζ chain through a spacer or hinge region.</p>
      </caption>
      <graphic xlink:href="gr1"/>
    </fig>
    <table-wrap position="float" id="tbl1">
      <label>Table 1</label>
      <caption>
        <p>Delivery systems</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left">Delivery system</th>
            <th align="center">Application</th>
            <th align="center">References</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left">Antibody</td>
            <td align="left">Targeting cytokines and toxins to specific Ag expressing cells/tissues</td>
            <td align="left">[<xref rid="bib1 bib2 bib3" ref-type="bibr">1,2<sup>•</sup>,3</xref>]</td>
          </tr>
          <tr>
            <td align="left">Latent molecules</td>
            <td align="left">Specific activity of proteins at sites of MMP activity</td>
            <td align="left">[<xref rid="bib4 bib5" ref-type="bibr">4<sup>•</sup>,5</xref>]</td>
          </tr>
          <tr>
            <td align="left">Protein transduction domains</td>
            <td align="left">Intracellular delivery of proteins, DNA, RNA to any cell type</td>
            <td align="left">[<xref rid="bib8 bib10 bib11 bib13" ref-type="bibr">8,10,11,13</xref>]</td>
          </tr>
          <tr>
            <td align="left">DNA vaccination</td>
            <td align="left">Recombinant vaccination through DNA expression of antigens</td>
            <td align="left">[<xref rid="bib26" ref-type="bibr">26</xref>]</td>
          </tr>
          <tr>
            <td align="left">Replicating viruses</td>
            <td align="left">Specific proliferation of viruses in tumour cells</td>
            <td align="left">[<xref rid="bib17 bib21" ref-type="bibr">17,21<sup>•</sup></xref>]</td>
          </tr>
          <tr>
            <td align="left">DNA/RNA complexes</td>
            <td align="left">Delivery of RNA or DNA to cells avoiding endosomal degradation</td>
            <td align="left">[<xref rid="bib38 bib39" ref-type="bibr">38,39</xref>]</td>
          </tr>
          <tr>
            <td align="left">T bodies</td>
            <td align="left">T cells engineered with chimeric receptors that target them to antigen bearing tumours or other cell types/tissues</td>
            <td align="left">[<xref rid="bib43 bib44 bib45 bib46" ref-type="bibr">43,44,45<sup>•</sup>,46</xref>]</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
  </floats-wrap>
</article>